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EDITORIAL
Diabetic nephropathy: Big and bad
Diabetic nephropathy is the single biggest cause of re-
nal failure in industrialized nations [1]. In its early stages
diabetic nephropathy is typified by renal hypertrophy,
increased glomerular filtration rate (GFR) (i.e., hyper-
filtration), and increased urinary albumin excretion [2,
3]. Later, as renal injury progresses, urinary albumin
excretion further increases and GFR progressively de-
clines, accompanied by pronounced mesangial expan-
sion, glomerulosclerosis, tubular atrophy, and interstitial
fibrosis [2, 3]. It has been presumed that early hyper-
trophic changes in the mesangium, endothelium [4], and
podocytes are integral to the subsequent development of
more severe renal histopathologic changes. Nevertheless,
the mechanisms initiating and regulating the functional
changes in these renal cells remain incompletely charac-
terized, and whether cell hypertrophy is a necessary an-
tecedant to the progression of diabetic nephropathy has
not been conclusively demonstrated.
Results from the Diabetes Control and Complications
Trial (DCCT) and United Kingdom Prospective Diabetes
Study (UKPDS) have clearly demonstrated that the oc-
currence of diabetic complications, including nephropa-
thy, are critically determined by glucose control [5, 6].
It has also been demonstrated that hyperglycemia, per
se, can result in hypertrophy of mesangial cells in vitro
[7–11]. Those studies further suggest that hyperglycemia
alters the expression of cyclin/cyclin-dependent kinase in-
hibitors, including p27Kip1 and p21cip1, important regula-
tors of the cell cycle contributing to renal cell hypertrophy
in diabetic state [7–11].
Regulation of the cycle occurs via cyclins and their in-
hibitors at multiple points along the sequential progres-
sion of the cell from rest (G0) into G1, S, G2, and M phases
[12, 13]. In G1the cell prepares for DNA duplication by
increasing protein synthesis. This phase is accompanied
by an increase in cell volume [14]. The cell then enters
S phase, duplicating its DNA. After preparing for mi-
tosis in the G2 phase, the cell divides into 2 daughter
cells (M phase), completing the cell cycle. Progression
through the cell cycle is regulated by a series of protein
kinases, including cyclins and cyclin-dependent kinases
[15]. In the mature kidney, the majority renal cells remain
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in the quiescent G0-phase [16, 17]. However, in the dia-
betic state, renal mesangial cells, podocyte, and tubular
epithelial cells are stimulated to actively enter the cell cy-
cle, but arrest in G1 with associated cell hypertrophy [11,
18, 19]. Previous studies using cultured cells demonstrate
an increase in cyclin/cyclin-dependent kinase inhibitors,
including p27Kip1, p21cip1 contributing to the G1 arrest
and renal hypertrophy in hyperglycemia [8, 10, 20, 21].
Does hyperglycemic-dependent renal hypertrophy
contribute to diabetic nephropathy? In this issue of Kid-
ney International, Wolf et al reported targeting disruption
of the p27Kip1 gene attenuates albuminuria, glomerular
sclerosis and mesangial, endothelial and podocyte hy-
pertrophy in a streptozotocin induced diabetic mouse
model [22]. Together with previous studies these findings
provide an in vivo link between renal hypertrophy and
the early changes of diabetic nephropathy. Nevertheless,
these short-term studies do not address whether block-
ing renal hypertrophy can forestall the progression of di-
abetic nephropathy to end-stage renal disease (ESRD).
It is important to note that only a subset of patients
with diabetes mellitus develop nephropathy, and clinical
observations linking diabetic renal hypertrophy to ESRD
are conflicting. Some clinical observations suggest renal
hypertrophy is a predictor of increased creatinine [23],
whereas other studies could not distinguish histomorpho-
logic correlates of renal hypertrophy in diabetic patients
prone to versus resistant to nephropathy [24]. Thus, ge-
netic factors may profoundly influence the progression
of diabetic nephropathy in humans [25, 26]. Similarly, re-
cent findings suggest genetic heterogeneity of diabetic
nephropathy in inbred mice [27–29]. Further studies of
p27kip1 knockouts bred onto mouse strains susceptible to
more advanced renal lesions should provide additional
insight into the contribution of renal hypertrophy to re-
nal disease in diabetic mellitus and help determine if, in
diabetes, big really is bad.
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